Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target

Survodutide and tirzepatide both build on GLP-1 receptor agonism — the same foundation behind semaglutide (Ozempic/Wegovy). But each drug adds a different second receptor, and that difference shapes everything from weight loss to liver effects.

Tirzepatide (Zepbound/Mounjaro) adds GIP — glucose-dependent insulinotropic polypeptide. It enhances insulin sensitivity, amplifies appetite suppression, and influences fat cell metabolism. This approach has produced the best weight loss results of any approved obesity drug: 22.5% at 72 weeks in SURMOUNT-1.

Survodutide adds glucagon — a hormone that increases energy expenditure and drives liver fat oxidation. This makes survodutide attack obesity from both sides of the energy equation: reduced intake (GLP-1) and increased output (glucagon). In Phase 2 trials, survodutide produced 18.7% weight loss at 46 weeks and an exceptional 83% MASH resolution rate.

Tirzepatide is FDA-approved and commercially available. Survodutide is in Phase 3 clinical trials and has not been approved.

Side-by-Side Comparison

How the Mechanisms Differ

Tirzepatide: GLP-1 + GIP

Tirzepatide activates two incretin hormone receptors: GLP-1 and GIP. The GLP-1 component reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. GIP amplifies the satiety signal, improves insulin sensitivity, and may directly influence fat cell metabolism. The net effect is powerful appetite suppression — patients eat significantly less and feel satisfied sooner.

This combination works primarily on the intake side of the energy balance equation. Tirzepatide does not increase how many calories the body burns at rest.

Survodutide: GLP-1 + Glucagon

Survodutide replaces GIP with glucagon — a fundamentally different approach. While GLP-1 handles appetite suppression and glucose control, glucagon adds metabolic effects that no pure incretin drug provides:

• Increased energy expenditure — glucagon stimulates thermogenesis, meaning the body burns more calories at rest
• Hepatic fat oxidation — glucagon acts directly on liver cells to break down stored fat, which is why survodutide shows exceptional results in MASH trials
• Glycogenolysis — glucagon triggers the liver to mobilize glycogen stores

The trade-off is that glucagon raises blood sugar — the opposite of what GLP-1 does. The drug is engineered so that GLP-1 counterbalances this glucose-raising effect, while the glucagon component adds its unique metabolic benefits.

Why This Matters

Tirzepatide makes you eat less. Survodutide makes you eat less and burn more. In theory, attacking both sides of the energy equation should produce more weight loss — but in practice, tirzepatide has produced better weight loss numbers so far. The likely explanation: tirzepatide has been tested at higher doses and for longer durations, and its Phase 3 data reflects a more optimized regimen than survodutide's Phase 2 data.

Weight Loss Comparison

What the Numbers Show

Tirzepatide has the larger weight loss number — 22.5% versus 18.7%. But several factors make this comparison indirect:

Different trial phases. Tirzepatide's 22.5% comes from a large Phase 3 trial (SURMOUNT-1, 2,539 participants). Survodutide's 18.7% comes from a smaller Phase 2 trial (387 participants). Phase 3 trials are generally more optimized — dose selection, titration schedules, and patient selection are all refined from Phase 2 learnings.

Different treatment durations. Tirzepatide was given for 72 weeks; survodutide for 46 weeks. Notably, survodutide's weight loss curve had not plateaued at 46 weeks, meaning longer treatment would likely have produced greater reductions.

Different dose titration. Survodutide used a 20-week dose escalation in Phase 2, which was relatively rapid and contributed to higher dropout rates. Phase 3 trials typically use slower titration, which could improve both tolerability and net weight loss.

Up to 40% of survodutide participants on the highest dose achieved 20% or more body weight loss at 46 weeks — a strong result for a Phase 2 trial that had not reached the weight loss plateau.

The only way to definitively compare these drugs would be a head-to-head randomized controlled trial. No such trial has been announced.

MASH and Liver Fat: Where Survodutide Stands Out

This is where the glucagon mechanism gives survodutide a distinct advantage. Both drugs have MASH trial data, and both show strong results — but through different mechanisms.

Survodutide MASH Data (Phase 2)

In the Phase 2 MASH trial, survodutide achieved:

• 83% MASH resolution without worsening fibrosis at 48 weeks
• Met its secondary endpoint for improvement in liver fibrosis
• The glucagon component drives direct hepatic fat oxidation — a mechanism that pure incretin drugs lack

Tirzepatide MASH Data (SYNERGY-NASH, Phase 2b)

In the SYNERGY-NASH trial, tirzepatide achieved at 52 weeks:

Comparing the MASH Results

Both drugs show impressive MASH resolution rates — survodutide at 83% and tirzepatide at 73.3% (highest dose). However, the same cross-trial caveats apply: different patient populations, different trial designs, and different assessment methods.

What is mechanistically clear is that survodutide's glucagon component provides direct liver-targeting effects that tirzepatide does not have. Glucagon drives hepatic fat oxidation at the cellular level. Tirzepatide's MASH benefits likely come primarily through weight loss and improved insulin sensitivity — indirect effects rather than direct hepatic action.

Both drugs have Phase 3 MASH programs underway. Survodutide is pursuing MASH as a major indication alongside obesity, reflecting Boehringer Ingelheim's strategic bet on the glucagon mechanism for liver disease.

Side Effects Comparison

The Discontinuation Rate Gap

Survodutide's Phase 2 discontinuation rate of 24.6% is notably high compared to tirzepatide's 4.3-7.1% in SURMOUNT-1. However, context matters significantly:

• Survodutide used a rapid 20-week dose escalation in Phase 2, which likely drove much of the GI intolerance
• Phase 3 trials typically employ slower titration schedules that improve tolerability
• This is Phase 2 vs Phase 3 data — titration optimization is one of the primary goals of Phase 2 trials

Whether survodutide's Phase 3 data will show improved tolerability remains to be seen. If the discontinuation rate stays high, it could limit the drug's real-world effectiveness regardless of its weight loss potential.

Where Retatrutide Fits

Both survodutide and tirzepatide are dual agonists — each targeting two receptors. Retatrutide is a triple agonist that targets all three: GLP-1, GIP, and glucagon. It combines everything both drugs offer into a single molecule.

Retatrutide produced 28.7% weight loss at 68 weeks in the TRIUMPH-4 Phase 3 trial — exceeding both survodutide and tirzepatide. Its liver fat reduction of 82.4% in Phase 2 is also the highest reported for any obesity drug.

The pattern is consistent with receptor biology: survodutide has glucagon (energy expenditure + liver) but not GIP. Tirzepatide has GIP (insulin + fat metabolism) but not glucagon. Retatrutide has both — and the additive effects appear to produce the strongest results across the board.

For detailed comparisons, see Retatrutide vs Tirzepatide and Retatrutide vs Survodutide.

Regulatory Status and Availability

Tirzepatide is available now. It can be prescribed by any licensed healthcare provider for approved indications. Survodutide is only available through clinical trial enrollment and cannot be purchased commercially. Any online sources claiming to sell survodutide are unregulated and potentially dangerous.

Frequently Asked Questions

Sources

1. Le Roux, C.W., et al. (2024). Survodutide for the treatment of obesity: a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. The Lancet Diabetes & Endocrinology. ClinicalTrials.gov (NCT04667377)
2. Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
3. Loomba, R., et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). New England Journal of Medicine. DOI: 10.1056/NEJMoa2401943
4. Boehringer Ingelheim. Survodutide Phase 2 MASH trial results. Boehringer Ingelheim
5. Eli Lilly. (2025). TRIUMPH-4 results. Press release
6. Eli Lilly. (2024). Tirzepatide was superior to placebo for MASH resolution (SYNERGY-NASH). Press release

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Survodutide is an investigational compound that has not been approved by the FDA or any regulatory authority. Tirzepatide is FDA-approved as Zepbound (obesity) and Mounjaro (type 2 diabetes). Always consult a healthcare provider before starting any medication. This site is not affiliated with Boehringer Ingelheim, Zealand Pharma, Eli Lilly, or any pharmaceutical manufacturer.